10-QPeriod: Q3 FY2024

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q3 Ended Sep 30, 2024

Filed October 31, 2024For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. reported solid financial results for the nine months ended September 30, 2024, with total revenues reaching $10.41 billion, an increase of 7.5% compared to the same period in the prior year. Net income also saw a significant rise, up 25% to $3.49 billion. This growth was driven by strong performance across key products, notably Dupixent and EYLEA HD, which showed substantial revenue increases of 25% and approximately 4% respectively in their respective segments. The company also saw positive growth in Libtayo and Praluent. Research and development expenses increased by approximately 14% year-over-year, reflecting continued investment in the company's pipeline. The company ended the period with a strong liquidity position, with $2.01 billion in cash and cash equivalents and $16.28 billion in marketable securities, while also actively repurchasing shares under its authorized program.

Financial Highlights

46 data points
Beta

Revenue

$3.72B

Net Income

$1.34B

36.0% Net Margin

EPS (Diluted)

$11.54

Total Assets

$37.44B

Cash & Equivalents

$2.01B

Free Cash Flow

$1.29B

Financial Statements
Beta
Revenue$3.72B
R&D Expenses$1.27B
SG&A Expenses$714.40M
Operating Expenses$2.54B
Operating Income$1.18B
Net Income$1.34B
EPS (Basic)$12.40
EPS (Diluted)$11.54
Shares Outstanding (Basic)108.10M
Shares Outstanding (Diluted)116.20M

Key Highlights

  • 1Total revenues for the nine months ended September 30, 2024, increased by 7.5% to $10.41 billion, driven by strong product sales and collaboration revenues.
  • 2Net income for the nine months ended September 30, 2024, rose by 25% to $3.49 billion, resulting in diluted earnings per share of $30.23.
  • 3Dupixent and Kevzara collaboration revenue experienced a significant increase of 23%, reflecting strong global sales performance.
  • 4EYLEA HD and EYLEA U.S. net product sales increased by 3.1% to $4.47 billion for the nine months ended September 30, 2024, driven by the launch of EYLEA HD.
  • 5Research and development expenses increased by 14% to $3.72 billion for the nine months ended September 30, 2024, indicating continued investment in pipeline development.
  • 6The company repurchased $1.64 billion of its common stock during the nine months ended September 30, 2024, under its share repurchase program.
  • 7Regeneron maintained a strong liquidity position with $2.01 billion in cash and cash equivalents and $16.28 billion in marketable securities as of September 30, 2024.

Frequently Asked Questions

Regeneron's revenue growth was primarily driven by strong performance in collaboration revenues, particularly from Dupixent and Kevzara, which saw a 23% increase. Additionally, net product sales for EYLEA HD and EYLEA in the U.S. increased by 3.1%, and Libtayo and Praluent also showed positive sales growth.

Research and development expenses increased by approximately 14% for the nine months ended September 30, 2024, compared to the same period in 2023, totaling $3.72 billion. This indicates a continued commitment to advancing its product pipeline.

As of September 30, 2024, Regeneron maintained a strong financial position with $2.01 billion in cash and cash equivalents and $16.28 billion in marketable securities. The company also had $1.98 billion in long-term debt.

Yes, Regeneron repurchased $1.64 billion of its common stock during the nine months ended September 30, 2024, under its authorized share repurchase program. As of that date, $2.89 billion remained available under a recently authorized repurchase program.